Log in

NASDAQ:RIGLRigel Pharmaceuticals Stock Price, Forecast & News

$1.77
+0.08 (+4.73 %)
(As of 04/10/2020 07:54 AM ET)
Add
Compare
Today's Range
$1.67
Now: $1.77
$1.79
50-Day Range
$1.27
MA: $1.80
$2.33
52-Week Range
$1.23
Now: $1.77
$3.10
Volume940,440 shs
Average Volume1.29 million shs
Market Capitalization$298.37 million
P/E RatioN/A
Dividend YieldN/A
Beta1.27
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia. Its clinical programs also comprise R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) program, which is in Phase I clinical study for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is based in South San Francisco, California.
Read More
Rigel Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.84 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RIGL
CUSIP76655960
Phone650-624-1100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$59.29 million
Book Value$0.32 per share

Profitability

Net Income$-66,890,000.00
Net Margins-112.83%

Miscellaneous

Employees158
Market Cap$298.37 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive RIGL News and Ratings via Email

Sign-up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.


Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

How has Rigel Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Rigel Pharmaceuticals' stock was trading at $1.81 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RIGL shares have decreased by 2.2% and is now trading at $1.77. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Rigel Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Rigel Pharmaceuticals.

When is Rigel Pharmaceuticals' next earnings date?

Rigel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Rigel Pharmaceuticals.

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced its quarterly earnings data on Thursday, February, 27th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.02. The biotechnology company had revenue of $15.40 million for the quarter, compared to analysts' expectations of $15.78 million. Rigel Pharmaceuticals had a negative return on equity of 90.30% and a negative net margin of 112.83%. During the same quarter in the previous year, the business earned $0.03 EPS. View Rigel Pharmaceuticals' earnings history.

What guidance has Rigel Pharmaceuticals issued on next quarter's earnings?

Rigel Pharmaceuticals updated its fourth quarter 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $15.4-15.4 million, compared to the consensus revenue estimate of $15.14 million.

What price target have analysts set for RIGL?

4 analysts have issued 1 year price objectives for Rigel Pharmaceuticals' stock. Their forecasts range from $7.00 to $8.00. On average, they expect Rigel Pharmaceuticals' stock price to reach $7.50 in the next year. This suggests a possible upside of 323.7% from the stock's current price. View analysts' price targets for Rigel Pharmaceuticals.

Has Rigel Pharmaceuticals been receiving favorable news coverage?

News headlines about RIGL stock have been trending very negative on Friday, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Rigel Pharmaceuticals earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutRigel Pharmaceuticals.

Who are some of Rigel Pharmaceuticals' key competitors?

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include Rite Aid (RAD), Inovio Pharmaceuticals (INO), Geron (GERN), Terra Tech (TRTC), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the following people:
  • Mr. Raul R. Rodriguez, Pres, CEO & Director (Age 58)
  • Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 54)
  • Dr. Anne-Marie S. Duliege, Exec. VP & Chief Medical Officer (Age 60)
  • Mr. Eldon C. Mayer III, M.B.A., Exec. VP & Chief Commercial Officer (Age 58)
  • Dr. Thomas A. Raffin, Co-Founder (Age 72)

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $1.77.

How big of a company is Rigel Pharmaceuticals?

Rigel Pharmaceuticals has a market capitalization of $298.37 million and generates $59.29 million in revenue each year. The biotechnology company earns $-66,890,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Rigel Pharmaceuticals employs 158 workers across the globe. View additional information about Rigel Pharmaceuticals.

What is Rigel Pharmaceuticals' official website?

The official website for Rigel Pharmaceuticals is http://www.rigel.com/.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]

This page was last updated on 4/10/2020 by MarketBeat.com Staff

Featured Article: Do You Need a Fiduciary?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel